The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Warrants

10 May 2023 17:48

RNS Number : 0110Z
Cellular Goods PLC
10 May 2023
 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

10 May 2023

 

Cellular Goods PLC

 

("Cellular Goods" or "the Company")

Grant of Warrants

Cellular Goods (LSE: CBX) a UK-based skincare and wellness company providing premium consumer products formulated with lab-produced cannabinoids, announces that it has granted Misha Sher, the Company's Non-Executive Director, a total of 2,000,000 warrants to subscribe for new ordinary shares of £0.001 each ('Warrants'). The Warrants are exercisable at 0.97 pence per ordinary share.

One third of the warrants will vest on 10 May 2024 with the remaining two thirds vesting in 24 equal monthly instalments thereafter. The Warrants have an exercise period from the date of grant to 10 May 2028.

Following the issue of the Warrants, the Company has a total of 59,460,000 warrants in issue.

 

For further information please contact:

Cellular Goods

Darcy Taylor

Chairman and interim CEO

Neil Thapar

Investor Relations

via Tancredi +44 207 887 7633

 

+44 787 645 5323

First Sentinel Corporate Finance

Corporate Broker & Advisor

Brian Stockbridge

 

+44 7876 888 011

Novum Securities

 

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Charlie Hobbs

cellulargoods@tancredigroup.com

 

+44 744 922 6720

+44 789 755 7112

 

About Cellular Goods PLC:

Cellular Goods develops and markets premium quality skincare and wellness products based on proprietary formulations incorporating biosynthetic lab-made cannabinoids. Our branded products are efficacy-led and research-backed and available online in the UK and US. The Company is incorporated in the UK and listed on the Main Market of the London Stock Exchange. For more information, visit www.cellular-goods.com.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Misha Sher

2.

Reason for the Notification

a)

Position/status

Non-executive director

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cellular Goods PLC

b)

LEI

213800IXPX4Z2MKX2U28

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of £0.001 each

ISIN

 ISIN: GB00BK964W87

b)

Nature of the transaction

Grant of warrants over 2,000,000 ordinary shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Exercise price of 0.97 pence per Ordinary Share

2,000,000

Ordinary Shares

d)

Aggregated information:

· Aggregated volume

· Price

 

2,000,000 Ordinary Shares

Exercise price of 0.97 pence per Ordinary Share

e)

Date of the transaction

10th May 2023

f)

Place of the Transaction

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHQBLFFXELZBBE
Date   Source Headline
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 202211:00 amRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSDirectorate change
14th Mar 20224:41 pmRNSSecond Price Monitoring Extn
14th Mar 20224:36 pmRNSPrice Monitoring Extension
14th Mar 20222:05 pmRNSSecond Price Monitoring Extn
14th Mar 20222:00 pmRNSPrice Monitoring Extension
14th Mar 20227:00 amRNSLaunch of outdoor marketing campaign
8th Mar 202211:03 amRNSShare purchase by CEO
7th Mar 202211:05 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
4th Mar 20224:41 pmRNSSecond Price Monitoring Extn
4th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSExercise of Warrants
1st Mar 20227:00 amRNSLaunch of Rejuvenating Cannabinoid Face Serum
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
23rd Feb 20222:06 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:01 pmRNSPrice Monitoring Extension
21st Feb 202211:05 amRNSSecond Price Monitoring Extn
21st Feb 202211:00 amRNSPrice Monitoring Extension
21st Feb 20229:05 amRNSSecond Price Monitoring Extn
21st Feb 20229:00 amRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSStrategy and trading update
2nd Feb 20227:00 amRNSWhite paper on cannabinoids and skin aging
7th Jan 20221:00 pmRNSResults of Annual General Meeting
15th Dec 20217:00 amRNSAnnual General Meeting update
8th Dec 20217:00 amRNSGrant of Options to CEO
6th Dec 20211:57 pmRNSPosting of Annual Report and Notice of AGM
6th Dec 20217:00 amRNSAppointment of new CEO
3rd Dec 20217:00 amRNSAnnual results
1st Dec 20217:00 amRNSLaunch of inaugural products & ecommerce platform
11th Nov 20217:00 amRNSAdvertising and PR agencies appointed
8th Nov 20212:05 pmRNSSecond Price Monitoring Extn
8th Nov 20212:00 pmRNSPrice Monitoring Extension
8th Nov 202111:05 amRNSSecond Price Monitoring Extn
8th Nov 202111:00 amRNSPrice Monitoring Extension
1st Nov 20217:00 amRNSGrant of Share Options and update on warrants
4th Oct 20219:06 amRNSSecond Price Monitoring Extn
4th Oct 20219:00 amRNSPrice Monitoring Extension
4th Oct 20217:00 amRNSDirector dealings & TR1 notification
16th Aug 20217:00 amRNSSupply agreement signed with Chanelle McCoy Health
2nd Aug 20217:00 amRNSShare disposal by significant shareholder
28th Jul 20212:06 pmRNSSecond Price Monitoring Extn
28th Jul 20212:00 pmRNSPrice Monitoring Extension
10th Jun 20217:00 amRNSSupply agreement signed with Willow Biosciences
25th May 20217:00 amRNSCellular Goods Interim Results
6th May 20217:00 amRNSGrant of Warrants and Extension of Exercise Period
20th Apr 20212:00 pmRNSPrice Monitoring Extension
12th Apr 20217:00 amRNSCellular Goods boosts team with five appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.